KyungdongPharm KRX:011040KOSDAQ
경동제약 · Korean news coverage and regulatory filings, organized.
Articles, 24h1
Articles, 7 days1
DART filings, 7 days0
Articles tracked1since Sep 11
In Q2 2026, KyungdongPharm reported revenue of ₩52.3bn, up 5.8% year on year, and operating profit of ₩3.7bn. KyungdongPharm (경동제약) appeared in 1 Korean news article and 0 DART filings over the past seven days. Coverage peaked on Sep 15 with 1 article.
KyungdongPharm quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩52.3bn | +5.8% | ₩3.7bn | ₩5.8bn |
| Q1 2026 | ₩47.8bn | +4.4% | ₩2.4bn | ₩4.7bn |
| Q4 2025 derived | ₩52.2bn | +5.3% | ₩2.6bn | ₩2.8bn |
| Q3 2025 | ₩48.9bn | -1.5% | ₩3.1bn | ₩4.4bn |
| Q2 2025 | ₩49.4bn | -0.6% | ₩478m | −₩423m |
| Q1 2025 | ₩45.8bn | +1.6% | ₩1.5bn | ₩1.6bn |
| Q4 2024 derived | ₩49.5bn | +10.6% | ₩2.2bn | ₩2.6bn |
| Q3 2024 | ₩49.6bn | +27.1% | ₩529m | ₩53m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
KyungdongPharm top stories 2 weeks, by number of outlets
- 1
